Abstract P1-11-18: The efficacy and safety of trastuzumab and pertuzumab in combination with different chemotherapy regimens for neoadjuvant treatment of HER2-posotive breast cancer: a multi-center real-world study in China

作者
Xiaowei Qi,Hong Hu,chen wenlin,xu yan,Shu Liu,Yanman Fang,Taolang Li,Jia Ming,zhou sihai,chai fan,liang yueyang,fan yuanming,Yi Zhang,Peng Tang,jiang jun,nie jianyun,Li Chen,Shushu Wang
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (5_Supplement): P1-11
标识
DOI:10.1158/1538-7445.sabcs22-p1-11-18
摘要

Abstract Background: Dual HER2 targeted therapy with trastuzumab (H) and pertuzumab (P) has been approved as neoadjuvant therapy for patients with HER2-positive breast cancer in China in 2019 based on the results from NeoSphere and PEONY study. However, the real-world efficacy and safety data are currently lack of evidence in China. Therefore, this multi-center real-world study aims to retrospectively analyze the efficacy and safety of neoadjuvant trastuzumab and pertuzumab combined with different chemotherapy regimens of HER2-positive early breast cancer. Methods: Patients received trastuzumab and pertuzumab in combination with different chemotherapy regimens, including taxanes (T), cyclophosphamide (C), anthracyclines (A) were collected retrospectively from 12 centers. The primary endpoint was total pathological complete response (tpCR, ypT0/is ypN0) rate. Results: A total of 357 patients were enrolled, among which 204 (57.5%) recieved TCbHP, 92 (25.9%) recieved EC-THP, and 51 (14.4%) received THP as chemotherapy regimens. The median age was 48 years old (range, 22-76), 142 (39.8%) of patients were classified as hormone receptor (HR)-positive, and 215 (60.2%) were HR-negative. The overall tpCR rate was 58.5% (95%CI, 53.2%-63.7%). tpCR rate for HR-negative patients was significantly higher than HR-positive patients (65.6% vs. 47.9%, p=0.001) and there was not any statistical difference according to chemotherapy regimens (56.9% for TCbHP, 56.5% for EC-THP, and 66.7% for THP, p=0.445). The most common adverse events included anemia (40.1%), white blood cell count decreased (34.3%), ejection fraction decreased (19.5%), Alanine aminotransferase increased (18.9%), platelet count decreased (12.8%) and neutrophil count decreased (12.0%). There was not any toxicity leading to death. Conclusions: Multi-center real-world data show satisfactory tpCR rate and tolerable adverse events of trastuzumab and pertuzumab in combination with different chemotherapy regimens in China. Citation Format: Xiaowei Qi, Hong Hu, chen wenlin, xu yan, liu shu, fang yanman, Taolang Li, ming jia, zhou sihai, chai fan, liang yueyang, fan yuanming, Yi Zhang, Peng Tang, jiang jun, nie jianyun, Li Chen, Shushu Wang. The efficacy and safety of trastuzumab and pertuzumab in combination with different chemotherapy regimens for neoadjuvant treatment of HER2-posotive breast cancer: a multi-center real-world study in China [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P1-11-18.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
ahxyk发布了新的文献求助10
1秒前
zhangkai6633发布了新的文献求助10
2秒前
SciGPT的应助被Postgraduate-Z采纳,获得10
3秒前
不舍天真发布了新的文献求助10
3秒前
爆米花的应助被苦柒采纳,获得10
4秒前
5秒前
可爱的函函的应助被Nowaki采纳,获得10
5秒前
含蓄乐菱关注了科研通微信公众号
5秒前
6秒前
跳舞的麦麦完成签到,获得积分10
6秒前
7秒前
Evander完成签到,获得积分10
7秒前
小马甲的应助被科研通管家采纳,获得10
7秒前
YW完成签到,获得积分10
8秒前
8秒前
科研通AI2S的应助被科研通管家采纳,获得10
8秒前
8秒前
伊啊亚完成签到,获得积分10
8秒前
Hello的应助被科研通管家采纳,获得10
8秒前
斯文若血发布了新的文献求助10
8秒前
null的应助被AURORA采纳,获得10
9秒前
FashionBoy的应助被科研通管家采纳,获得10
10秒前
田様的应助被不舍天真采纳,获得10
10秒前
香蕉觅云的应助被科研通管家采纳,获得10
10秒前
10秒前
华仔的应助被科研通管家采纳,获得10
10秒前
molihuakai的应助被科研通管家采纳,获得10
10秒前
10秒前
wanci的应助被科研通管家采纳,获得30
10秒前
无极微光的应助被科研通管家采纳,获得20
10秒前
Ava的应助被科研通管家采纳,获得10
11秒前
11秒前
Orange的应助被科研通管家采纳,获得10
11秒前
11秒前
烟花的应助被科研通管家采纳,获得10
11秒前
11秒前
我是老大的应助被科研通管家采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163922
求助须知:如何正确求助?哪些是违规求助? 9557995
关于积分的说明 21743022
捐赠科研通 7754548
什么是DOI,文献DOI怎么找? 3428401
关于科研通互助平台的介绍 2553053
邀请新用户注册赠送积分活动 2473008